Sol-Gel Technologies Ltd.
SLGLHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland,. Valued at $227.4M, SLGL is a micro-cap name in its sector. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea.
Market Cap
$227.4M
Beta
1.15
P/E (TTM)
—
P/E (Fwd)
-8.65
EPS (TTM)
$-5.75
EPS (Fwd)
$-8.03
ROE
-40.8%
ROA
-23.9%
Cash
$47.9M
Total Debt
$770,000
Free CF
-$2.1M
52W Change
78.1%
Annual Financials
Cash vs Debt
Where SLGL stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SLGL finished 12.38% below its 150-day moving average ($74.16) and 11.52% below its 200-day moving average ($73.44). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SLGL overbought or oversold?
At the October 20, 2026 close, SLGL's RSI(14) was 39.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $47.9M in cash and $770K in debt, SLGL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$2.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -40.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $3.9M (2022) to $19.4M (2025), reflecting a 399% increase over the period.
With cash comfortably exceeding debt, SLGL has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Sol-Gel Technologies Ltd.'s trajectory.